Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABB i5
- Development stage
- Unknown
- Modality
- Microbiome Therapeutics
- Administration
- Oral
01
Overview
ABB i5 is a prebiotic, a type of dietary supplement designed to selectively stimulate the growth and/or activity of beneficial microorganisms in the gut. It is being investigated for its potential to manage constipation and improve overall gastrointestinal well-being through its effects on the gut microbiota. It has been studied in a pilot trial in combination with the postbiotic ABB C22.
Beyond the preview
Go deeper on ABB i5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABB i5.